Table 2.
Marker | Outcomes | Analysisa | Histologyb | Studies | Random Effects Model | Heterogeneity | |||
---|---|---|---|---|---|---|---|---|---|
Overall effect (95% CIs) | P value | I2 (%) | τ2 | P value | |||||
Podoplanin | OS/DSS | U | A | 6 | 2.49 (1.90–3.26) | < 0.001 | 0 | 0.00 | 0.74 |
S | 3 | 1.78 (0.91–3.48) | 0.093 | 58 | 0.20 | 0.093 | |||
M | A | 3 | 1.28 (0.67–2.45) | 0.460 | 68 | 0.20 | 0.05 | ||
S | 2 | 2.50 (1.58–3.95) | < 0.001 | 0 | 0.00 | 0.59 | |||
RFS/DFS | U | A | 3 | 3.12 (2.17–4.49) | < 0.001 | 10 | 0.01 | 0.33 | |
S | 3 | 2.30 (1.55–3.42) | < 0.001 | 0 | 0.00 | 0.89 | |||
M | A | 3 | 2.59 (1.19–5.65) | 0.020 | 46 | 0.22 | 0.16 | ||
S | 2 | 2.04 (1.30–3.18) | 0.002 | 0 | 0.00 | 0.94 | |||
α-SMA | OS/DSS | U | A | 2 | 5.91 (3.49–10.00) | < 0.001 | 22 | 0.04 | 0.26 |
aU univariate, M multivariate.
bA adenocarcinoma, S squamous.